Benjamin Joseph Moss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benjamin Joseph Moss has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sboner
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
1 shared publication - Annette M. McGehee
Suffolk University, Boston, Massachusetts, United States
1 shared publication - Ashutosh Tewari
Weill Medical College of Cornell University
1 shared publication - Daniel M. Musher
Veterans Affairs Medical Center
1 shared publication - David Z Chen
Program in Computational Biology and Bioinformatics, Yale University, 300 George Street, New Haven, CT 06511, USA
1 shared publication - Dorothee Pflueger
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 12 January 2021
- Published by Springer Nature in Research Square
Candida Species in Community-Acquired Pneumonia in Patients With Chronic Aspiration
BackgroundWhen Candida is found in a sputum culture, clinicians generally dismiss it as a contaminant. We sought to identify cases of community-acquired pneumonia (CAP) in which Candida might play a contributory etiologic role.MethodsIn a convenience sample of patients hospitalized for CAP, we screened for “high-quality sputum” by Gram stain (>20 WBC/epithelial cell) and performed quantitative sputum cultures. Criteria for a potential etiologic role for Candida included the observation of large numbers of yeast forms on Gram stain and the finding of >106 CFU/ml Candida in sputum. We gathered clinical information on cases that met these criteria for possible Candida infection.ResultsSputum from 6 of 154 consecutive CAP patients had large numbers of extra- and intracellular yeast forms on Gram stain, with >106 CFU/ml Candida albicans, glabrata, or tropicalis on quantitative culture. In all 6 patients, the clinical diagnoses at admission included chronic aspiration. Greater than 105 CFU/ml of a recognized bacterial pathogen (Streptococcus pneumoniae, Staphylococcus aureus, or Pseudomonas) or >106 CFU/ml of other ‘normal respiratory flora’ (Lactobacillus species) were present together with Candida in every case. Blood cultures yielded Candida in 1 case, and 1,3-beta-D glucan was >500 ng/mL in 3 of 3 cases in which it was assayed. Since all patients were treated with anti-bacterial and anti-fungal drugs, no inference about etiology can be derived from therapeutic response.ConclusionsCandida species, together with a recognized bacterial pathogen or normal respiratory flora, may contribute to the cause of CAP in patients who chronically aspirate.
- 12 January 2021
- Published by Springer Nature in Research Square
Open AccessCandida Species in Community-Acquired Pneumonia in Patients With Chronic Aspiration
BackgroundWhen Candida is found in a sputum culture, clinicians generally dismiss it as a contaminant. We sought to identify cases of community-acquired pneumonia (CAP) in which Candida might play a contributory etiologic role.MethodsIn a convenience sample of patients hospitalized for CAP, we screened for “high-quality sputum” by Gram stain (>20 WBC/epithelial cell) and performed quantitative sputum cultures. Criteria for a potential etiologic role for Candida included the observation of large numbers of yeast forms on Gram stain and the finding of >106 CFU/ml Candida in sputum. We gathered clinical information on cases that met these criteria for possible Candida infection.ResultsSputum from 6 of 154 consecutive CAP patients had large numbers of extra- and intracellular yeast forms on Gram stain, with >106 CFU/ml Candida albicans, glabrata, or tropicalis on quantitative culture. In all 6 patients, the clinical diagnoses at admission included chronic aspiration. Greater than 105 CFU/ml of a recognized bacterial pathogen (Streptococcus pneumoniae, Staphylococcus aureus, or Pseudomonas) or >106 CFU/ml of other ‘normal respiratory flora’ (Lactobacillus species) were present together with Candida in every case. Blood cultures yielded Candida in 1 case, and 1,3-beta-D glucan was >500 ng/mL in 3 of 3 cases in which it was assayed. Since all patients were treated with anti-bacterial and anti-fungal drugs, no inference about etiology can be derived from therapeutic response.ConclusionsCandida species, together with a recognized bacterial pathogen or normal respiratory flora, may contribute to the cause of CAP in patients who chronically aspirate.
- Open Access
- 1 July 2015
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 67, 66-74
The DAF-7/TGF-β signaling pathway regulates abundance of the Caenorhabditis elegans glutamate receptor GLR-1
- 1 July 2015
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 67, 66-74
Open AccessThe DAF-7/TGF-β signaling pathway regulates abundance of the Caenorhabditis elegans glutamate receptor GLR-1
- Open Access
- 21 October 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (10) , R104
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data
We have developed FusionSeq to identify fusion transcripts from paired-end RNA-sequencing. FusionSeq includes filters to remove spurious candidate fusions with artifacts, such as misalignment or random pairing of transcript fragments, and it ranks candidates according to several statistics. It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including eight cancers with and without known rearrangements.
- 21 October 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (10) , R104
Open AccessFusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data
We have developed FusionSeq to identify fusion transcripts from paired-end RNA-sequencing. FusionSeq includes filters to remove spurious candidate fusions with artifacts, such as misalignment or random pairing of transcript fragments, and it ranks candidates according to several statistics. It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including eight cancers with and without known rearrangements.